Amyotrophic lateral sclerosis (ALS) is a fatal and intricate neurodegenerative disease that impacts upper and lower motor neurons within the central nervous system, leading to their progressive destruction. Despite extensive research, the pathogenesis of this multifaceted disease remains elusive. The United States Food and Drug Administration (FDA) has granted approval for seven medications designed to address ALS and mitigate its associated symptoms. These FDA-sanctioned treatments are Qalsody, Relyvrio, Radicava, Rilutek, Tiglutik, Exservan, and Nuedexta. In this review, the effects of these seven drugs on ALS based on their mechanism of action, dosing, and clinical presentations are comprehensively summarized. Each medication offers a distinct approach to manage ALS, aiming to alleviate the burdensome symptoms and slow the disease's progression, thereby improving the quality of life for individuals affected by this neurological condition. However, despite these advancements in pharmaceutical interventions, finding a definitive cure for ALS remains a significant challenge. Continuous investigation into ALS pathophysiology and therapeutic avenues remains imperative, necessitating further research collaborations and innovative approaches to unravel the complex mechanisms underlying this debilitating condition.
Citation: Ubaid Ansari, Meraj Alam, Dawnica Nadora, Zohaer Muttalib, Vincent Chen, Isabel Taguinod, Megan FitzPatrick, Jimmy Wen, Zaid Ansari, Forshing Lui. Assessing the efficacy of amyotrophic lateral sclerosis drugs in slowing disease progression: A literature review[J]. AIMS Neuroscience, 2024, 11(2): 166-177. doi: 10.3934/Neuroscience.2024010
Amyotrophic lateral sclerosis (ALS) is a fatal and intricate neurodegenerative disease that impacts upper and lower motor neurons within the central nervous system, leading to their progressive destruction. Despite extensive research, the pathogenesis of this multifaceted disease remains elusive. The United States Food and Drug Administration (FDA) has granted approval for seven medications designed to address ALS and mitigate its associated symptoms. These FDA-sanctioned treatments are Qalsody, Relyvrio, Radicava, Rilutek, Tiglutik, Exservan, and Nuedexta. In this review, the effects of these seven drugs on ALS based on their mechanism of action, dosing, and clinical presentations are comprehensively summarized. Each medication offers a distinct approach to manage ALS, aiming to alleviate the burdensome symptoms and slow the disease's progression, thereby improving the quality of life for individuals affected by this neurological condition. However, despite these advancements in pharmaceutical interventions, finding a definitive cure for ALS remains a significant challenge. Continuous investigation into ALS pathophysiology and therapeutic avenues remains imperative, necessitating further research collaborations and innovative approaches to unravel the complex mechanisms underlying this debilitating condition.
| [1] |
Masrori P, Van Damme P (2020) Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol 27: 1918-1929. https://doi.org/10.1111/ene.14393 
|
| [2] |
Tzeplaeff L, Wilfling S, Requardt MV, et al. (2023) Current State and Future Directions in the Therapy of ALS. Cells 12: 1523. https://doi.org/10.3390/cells12111523
|
| [3] |
Blair HA (2023) Tofersen: First Approval. Drugs 83: 1039-1043. https://doi.org/10.1007/s40265-023-01904-6
|
| [4] |
Benedetto Tiz D, Bagnoli L, Rosati O, et al. (2022) FDA-Approved Small Molecules in 2022: Clinical Uses and Their Synthesis. Pharmaceutics 14: 2538. https://doi.org/10.3390/pharmaceutics14112538
|
| [5] | Neupane P, Thada PK, Singh P, et al. (2023) Investigating Edaravone Use for Management of Amyotrophic Lateral Sclerosis (ALS): A Narrative Review. Cureus 15: e33746. https://doi.org/10.7759/cureus.33746 |
| [6] |
Bellingham MC (2011) A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?. CNS Neurosci Ther 17: 4-31. https://doi.org/10.1111/j.1755-5949.2009.00116.x
|
| [7] |
Brooks BR, Bettica P, Cazzaniga S (2019) Riluzole Oral Suspension: Bioavailability Following Percutaneous Gastrostomy Tube-modeled Administration Versus Direct Oral Administration. Clin Ther 41: 2490-2499. https://doi.org/10.1016/j.clinthera.2019.09.016
|
| [8] |
Wymer J, Apple S, Harrison A, et al. (2023) Pharmacokinetics, Bioavailability, and Swallowing Safety With Riluzole Oral Film. Clin Pharmacol Drug Dev 12: 57-64. https://doi.org/10.1002/cpdd.1168
|
| [9] | Sun Y, Benatar M, Mascías Cadavid J, et al. (2023) ALSUntangled #71: Nuedexta. Amyotroph Lateral Scler Frontotemporal Degener 26: 1-5. https://doi.org/10.1080/21678421.2023.2239292 |
| [10] |
Eleutherio ECA, Silva Magalhães RS, de Araújo Brasil A, et al. (2021) SOD1, more than just an antioxidant. Arch Biochem Biophys 697: 108701. https://doi.org/10.1016/j.abb.2020.108701
|
| [11] |
Bunton-Stasyshyn RKA, Saccon RA, Fratta P, et al. (2015) SOD1 function and its implications for amyotrophic lateral sclerosis pathology: New and renascent themes. Neuroscientist 21: 519-529. https://doi.org/10.1177/1073858414561795
|
| [12] |
Rinaldi C, Wood MJA (2018) Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol 14: 9-21. https://doi.org/10.1038/nrneurol.2017.148
|
| [13] |
Miller TM, Cudkowicz ME, Genge A, et al. (2022) Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med 387: 1099-1110. https://doi.org/10.1056/NEJMoa2204705
|
| [14] |
Blair HA (2023) Tofersen: First approval. Drugs 83: 1039-1043. https://doi.org/10.1007/s40265-023-01904-6
|
| [15] |
Miller T, Cudkowicz M, Shaw PJ, et al. (2020) Phase 1–2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med 383: 109-119. https://doi.org/10.1056/NEJMoa2003715
|
| [16] |
Benatar M, Wuu J, Andersen PM, et al. (2022) Design of a randomized, placebo-controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: The ATLAS study. Neurotherapeutics 19: 1248-1258. https://doi.org/10.1007/s13311-022-01237-4
|
| [17] | Fels JA, Dash J, Leslie K, et al. (2022) Effects of the Investigational Drug Sodium Phenylbutyrate-TUDCA (AMX0035) on the Transcriptional and Metabolic Landscape of Sporadic ALS Fibroblasts. Neuroscience . https://doi.org/10.1101/2022.05.02.490306 |
| [18] |
Mead RJ, Shan N, Reiser HJ, et al. (2023) Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. Nat Rev Drug Discov 22: 185-212. https://doi.org/10.1038/s41573-022-00612-2
|
| [19] | Soares R, Ribeiro FF, Xapelli S, et al. (2018) Tauroursodeoxycholic Acid Enhances Mitochondrial Biogenesis, Neural Stem Cell Pool, and Early Neurogenesis in Adult Rats. Mol Neurobiol 55: 3725-3738. https://doi.org/10.1007/s12035-017-0592-5 |
| [20] |
Yam GHF, Gaplovska-Kysela K, Zuber C, et al. (2007) Sodium 4-phenylbutyrate acts as a chemical chaperone on misfolded myocilin to rescue cells from endoplasmic reticulum stress and apoptosis. Invest Ophthalmol Vis Sci 48: 1683. https://doi.org/10.1167/iovs.06-0943
|
| [21] | Sodium Phenylbutyrate and TaurursodiolAmerican Journal of Health-System Pharmacy (2023)80: 316-318. https://doi.org/10.1093/ajhp/zxac363 |
| [22] |
Paganoni S, Macklin EA, Hendrix S, et al. (2020) Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis. N Engl J Med 383: 919-930. https://doi.org/10.1056/NEJMoa1916945
|
| [23] |
Cho H, Shukla S (2020) Role of edaravone as a treatment option for patients with amyotrophic Lateral Sclerosis. Pharmaceuticals (Basel) 14: 29. https://doi.org/10.3390/ph14010029
|
| [24] |
Beal MF, Ferrante RJ, Browne SE, et al. (1997) Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol 42: 644-654. https://doi.org/10.1002/ana.410420416
|
| [25] |
Cipak Gasparovic A, Zarkovic N, Zarkovic K, et al. (2017) Biomarkers of oxidative and nitro-oxidative stress: conventional and novel approaches. Br J Pharmacol 174: 1771-1783. https://doi.org/10.1111/bph.13673
|
| [26] |
Yamamoto Y, Kuwahara T, Watanabe K, et al. (1996) Antioxidant activity of 3-methyl-1-phenyl-2-pyrazolin-5-one. Redox Rep 2: 333-338. https://doi.org/10.1080/13510002.1996.11747069
|
| [27] |
Jami MS, Salehi-Najafabadi Z, Ahmadinejad F, et al. (2015) Edaravone leads to proteome changes indicative of neuronal cell protection in response to oxidative stress. Neurochem Int 90: 134-141. https://doi.org/10.1016/j.neuint.2015.07.024
|
| [28] | PubChem. PRDX2 - peroxiredoxin 2 (human). Accessed December 30, 2023. Available from: https://pubchem.ncbi.nlm.nih.gov/gene/PRDX2/human |
| [29] |
Yoshino H, Kimura A (2006) Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study). Amyotroph Lateral Scler 7: 241-245. https://doi.org/10.1080/17482960600881870
|
| [30] |
Abe K, Itoyama Y, Sobue G, et al. (2014) Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener 15: 610-617. https://doi.org/10.3109/21678421.2014.959024
|
| [31] | THE EDARAVONE (MCI-186) ALS 16 STUDY GROUP.A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener (2017) 18(sup1): 11-19. https://doi.org/10.1080/21678421.2017.1363780 |
| [32] | Writing Group, Edaravone (MCI-186) ALS 19 Study Group.Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled trial. Lancet Neurol (2017) 16: 505-512. https://doi.org/10.1016/S1474-4422(17)30115-1 |
| [33] | Fda.gov. Accessed January 11, 2024. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020599s011s012lbl.pdf |
| [34] |
Rattray M, Bendotti C (2006) Does excitotoxic cell death of motor neurons in ALS arise from glutamate transporter and glutamate receptor abnormalities?. Exp Neurol 201: 15-23. https://doi.org/10.1016/j.expneurol.2006.05.001
|
| [35] |
Zona C, Siniscalchi A, Mercuri NB, et al. (1998) Riluzole interacts with voltage-activated sodium and potassium currents in cultured rat cortical neurons. Neuroscience 85: 931-938. https://doi.org/10.1016/S0306-4522(97)00604-0
|
| [36] |
Liu AYC, Mathur R, Mei N, et al. (2011) Neuroprotective drug riluzole amplifies the heat shock factor 1 (HSF1)- and glutamate transporter 1 (GLT1)-dependent cytoprotective mechanisms for neuronal survival. J Biol Chem 286: 2785-2794. https://doi.org/10.1074/jbc.M110.158220
|
| [37] |
Foran E, Trotti D (2009) Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis. Antioxid Redox Signal 11: 1587-1602. https://doi.org/10.1089/ars.2009.2444
|
| [38] |
Bensimon G, Lacomblez L, Meininger V (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 330: 585-591. https://doi.org/10.1056/NEJM199403033300901
|
| [39] |
Lacomblez L, Bensimon G, Leigh PN, et al. (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 347: 1425-1431. https://doi.org/10.1016/S0140-6736(96)91680-3
|
| [40] |
Takei K, Tsuda K, Takahashi F, et al. (2017) An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe. Amyotroph Lateral Scler Frontotemporal Degener 18: 88-97. https://doi.org/10.1080/21678421.2017.1361445
|
| [41] | Inácio P (2023) Early 2024 eyed for approval decision in EU on masitinib for ALS. ALS News Today . Available from: https://alsnewstoday.com/news/early-2024-likely-masitinib-eu-conditional-approval-decision-als/ |
| [42] |
Mora JS, Genge A, Chio A, et al. (2020) Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener 21: 5-14. https://doi.org/10.1080/21678421.2019.1632346
|
| [43] |
An S, Lee W, Yoo B (2023) Comparison of national dysphagia diet and international dysphasia diet standardization initiative levels for thickened drinks prepared with a commercial xanthan gum-based thickener used for patients with dysphagia. Prev Nutr Food Sci 28: 83-88. https://doi.org/10.3746/pnf.2023.28.1.83
|
| [44] |
Povedano Panades M, Couratier P, Sidle K, et al. (2021) Administration of riluzole oral suspension during the different stages of amyotrophic lateral sclerosis. Front Neurol 12. https://doi.org/10.3389/fneur.2021.633854
|
| [45] |
Brooks BR, Bettica P, Cazzaniga S (2019) Riluzole oral suspension: Bioavailability following percutaneous gastrostomy tube-modeled administration versus direct oral administration. Clin Ther 41: 2490-2499. https://doi.org/10.1016/j.clinthera.2019.09.016
|
| [46] |
Keating GM (2016) Riluzole oral suspension in amyotrophic lateral sclerosis: a guide to its use. Drugs Ther Perspect 32: 282-286. https://doi.org/10.1007/s40267-016-0312-7
|
| [47] |
Onesti E, Schettino I, Gori MC, et al. (2017) Dysphagia in amyotrophic lateral sclerosis: Impact on patient behavior, diet adaptation, and riluzole management. Front Neurol 8. https://doi.org/10.3389/fneur.2017.00094
|
| [48] |
Calvo AC, Valledor-Martín I, Moreno-Martínez L, et al. (2022) Lessons to Learn from the Gut Microbiota: A Focus on Amyotrophic Lateral Sclerosis. Genes (Basel) 13: 865. https://doi.org/10.3390/genes13050865
|
| [49] |
Bissaro M, Moro S (2019) Rethinking to riluzole mechanism of action: the molecular link among protein kinase CK1δ activity, TDP-43 phosphorylation, and amyotrophic lateral sclerosis pharmacological treatment. Neural Regen Res 14: 2083-2085. https://doi.org/10.4103/1673-5374.262578
|
| [50] | Drug and Device News. P T 43: 588-598. |
| [51] | Oh SR, Agrawal S, Sabir S, et al. (2023) Dextromethorphan. [Updated 2023 May 22]. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538216/ |
| [52] | Jain A, SISODIA J (2023) Quinidine. StatPearls. Treasure Island (FL): StatPearls Publishing. |
| [53] | Cruz MP (2013) Nuedexta for the treatment of pseudobulbar affect: a condition of involuntary crying or laughing. P T 38: 325-328. |
| [54] | Ahmed A, Simmons Z (2013) Pseudobulbar affect: prevalence and management. Ther Clin Risk Manag 9: 483-489. https://doi.org/10.2147/TCRM.S53906 |
Ubaid Ansari, Meraj Alam, Dawnica Nadora, Zohaer Muttalib, Vincent Chen, Isabel Taguinod, Megan FitzPatrick, Jimmy Wen, Zaid Ansari, Forshing Lui. Assessing the efficacy of amyotrophic lateral sclerosis drugs in slowing disease progression: A literature review[J]. AIMS Neuroscience, 2024, 11(2): 166-177. doi: 10.3934/Neuroscience.2024010
DownLoad: